EF Hutton Initiates Coverage On Marinus Pharma With Buy Rating, Announces Price Target of $23
EF Hutton Initiates Coverage On Marinus Pharma With Buy Rating, Announces Price Target of $23
EF Hutton发起对Marinus Pharma的覆盖,给予买入评级,并宣布目标股价为23美元
EF Hutton analyst Jason Kolbert initiates coverage on Marinus Pharma (NASDAQ:MRNS) with a Buy rating and announces Price Target of $23.
EF Hutton分析师Jason Kolbert开始对Marinus Pharma(纳斯达克:MRNS)进行买入评级,并宣布目标股价为$23。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。